The PDF brochure for the Pharmaceutical Drug Pricing Strategies Summit is now available. Download it now

2019 Topic Areas Include:

Drug Price Transparency Laws and Policies

Medicare and Medicaid Drug Pricing Models

Value-Based Pricing and Reimbursement

Multi-stakeholder initiatives for patient access

  • May 8th

    CMS announced a final rule that requires drug manufacturers to provide the list price for their products in direct-to-consumer ads.

  • June 14th

    A coalition of pharmaceutical companies sued HHS on the final ruling, arguing that advertising list prices is a violation of the first amendment and does not account for the differences among insurance plans.

  • July 8th

    A federal judge ruled listing drug prices in DTC ads are unlawful.

  • July 11th

    The Trump administration withdrew plans to eliminate drug price rebates.

  • July 23rd

    A key senate committee unveiled a long-awaited package of drug pricing reforms that would cap how much drug makers can raise their prices in Medicare. It would also cap out-of-pocket expenses for Medicare beneficiaries and dramatically reform the program's prescription drug benefit.

  • August 21st

    HHS appealed against the federal court's decision to block the HHS final rule that required manufacturer's to disclose product list prices within DTC ads.

  • On-going

    On Going- High drug prices will remain a centerpiece issue for politicians and Patients. Stay up to date with recent drug price transparency trends!

Participating Organizations

Executive Partner

Supporting Partner


Call for Papers

Submit Abstract for Presentations

Pharmaceutical Drug Pricing Strategies Summit is now accepting abstract submissions for 2019!

Deadline is July 19th, 2019.